REV-ERB agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-11-04. Numbers and descriptions here follow the published literature rather than marketing material.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
== Career == After the break-up of the Beat in 1983 (known as the English Beat in North America), vocalists Dave Wakeling and Ranking Roger decided to continue working together in a new venture. They joined up with keyboardist Mickey Billingham (Dexys Midnight Runners), guitarist Mick Jones (the Clash), bassist Horace Panter (the Specials) and drummer Stoker (Dexys Midnight Runners/the Bureau) to form a supergroup of the UK punk and ska scene. They named the band General Public and were rapidly signed to Virgin Records in the UK and I.R.S. Records in North America. The band recorded and released the album All the Rage in 1984. Jones left General Public part way through the recording process, but he is listed in the album's inner sleeve credits as a group member (although he did not appear in any of the band photographs for the album cover). Jones' replacement, guitarist Kevin White, also played on the album and was also listed as an official group member. White's picture also appeared on the album's back cover. In the UK, General Public had a minor hit with the track "General Public", which reached No. 60 in the UK singles chart in 1984. The single's B-side "Dishwasher" (an instrumental mix of "Burning Bright" from All The Rage) became a surprise Top 40 hit in the Netherlands, after its use as a closing theme tune to the pop radio show Avondspits. Later in the year, the band fared even better in North America, where their second single "Tenderness" was a Top 30 hit in Canada (No. 11) and the US (No. 27).
=== αvβ6-integrin target === The abundance of αvβ6-integrin on most adult human cell types and respective tissues is low. It is however overexpressed in the context of several medical conditions, such as cancer or fibrosis, particularly idiopathic pulmonary fibrosis. In line with the finding that αvβ6-integrin is expressed by epithelial cells, an elevated density of the protein is observed on the cell surfaces of many carcinomas (synonymous to cancers of epithelial origin). Hence, 68Ga-Trivehexin can be used for PET imaging of αvβ6-integrin positive cancers (i.e., those whose cells possess a sufficiently high density of αvβ6 on their surface), including but not limited to pancreatic ductal adenocarcinoma, non-small cell lung cancer, squamous cell carcinomas (SCC) of different origin (most notably, oral and esophageal SCC), as well as breast, ovarian, and bladder cancer. In colorectal cancer, expression of αvβ6-integrin is higher in the more aggressive forms and correlated with reduced overall survival. 68Ga-Trivehexin has a high binding affinity to αvβ6-integrin (IC50 = 0.047 nM). Its affinity to other RGD-binding integrins is much lower (IC50 for αvβ3, αvβ8, and α5β1 are 2.7, 6.2, and 22 nM, respectively; note that for IC50, higher values mean lower affinity), resulting in a high selectivity for αvβ6-integrin.
Photoactivated peptides are modified natural or synthetic peptides whose functions can be activated or controlled using light. These peptides incorporate light-sensitive elements that allow for precise regulation their biological activity in both space and time. The activation can be either irreversible, as in the case of caged peptides with photocleavable protecting groups, or reversible, utilizing molecular photoswitches like azobenzenes or diarylethenes, and diarylethenes By incorporating these light-responsive components into the peptide structure, peptide properties, functions, and biological activities can be manipulated with high precision. This approach enables targeted activation of peptides in specific areas, making photoactivated peptides valuable tools for applications in cancer therapy, drug delivery, and probing molecular interactions in living cells and in organisms.
Amphibians are a class of animals comprising frogs, salamanders and caecilians. They are tetrapods, but the caecilians and a few species of salamander have either no limbs or their limbs are much reduced in size. Their main bones are hollow and lightweight and are fully ossified and the vertebrae interlock with each other and have articular processes. Their ribs are usually short and may be fused to the vertebrae. Their skulls are mostly broad and short, and are often incompletely ossified. Their skin contains little keratin and lacks scales, but contains many mucous glands and in some species, poison glands. The hearts of amphibians have three chambers, two atria and one ventricle. They have a urinary bladder and nitrogenous waste products are excreted primarily as urea. Amphibians breathe by means of buccal pumping, a pump action in which air is first drawn into the buccopharyngeal region through the nostrils. These are then closed and the air is forced into the lungs by contraction of the throat. They supplement this with gas exchange through the skin which needs to be kept moist. In frogs the pelvic girdle is robust and the hind legs are much longer and stronger than the forelimbs. The feet have four or five digits and the toes are often webbed for swimming or have suction pads for climbing. Frogs have large eyes and no tail. Salamanders resemble lizards in appearance; their short legs project sideways, the belly is close to or in contact with the ground and they have a long tail. Caecilians superficially resemble earthworms and are limbless.
In relation to this, MDMA's duration and the offset of its effects appear to be determined more by rapid acute tolerance rather than by circulating drug concentrations. Similar findings have been made for amphetamine and methamphetamine. One mechanism by which tolerance to MDMA may occur is internalization of the serotonin transporter (SERT). Although MDMA and serotonin are not significant TAAR1 agonists in humans, TAAR1 activation by MDMA may result in SERT internalization, for instance in rodents in whom MDMA is a potent TAAR1 agonist. It is thought that brain serotonin levels are depleted after MDMA administration but that levels typically return to normal within 24 to 48 hours.
Sources: en.wikipedia.org
=== Über den Zufall. Jean Paul, Hölderlin und der Roman, den ich schreibe (2012) === Dein Name ist eng verwoben mit Kermanis Frankfurter Poetikvorlesungen aus dem Sommersemester 2010, die sich als Vorrede zum Roman lesen lassen (sie enthalten u. a. kommentierte Manuskriptpassagen des Romans, der wiederum aus den Vorlesungen zitiert und diese kommentiert). In den unter dem Titel Über den Zufall. Jean Paul, Hölderlin und der Roman, den ich schreibe 2012 auch als Buch veröffentlichten fünf Vorlesungen wird weniger Bilanz gezogen als vielmehr die zukünftige Poetik des unabgeschlossenen Romanprojekts Dein Name erkundet. Jean Paul und Friedrich Hölderlin repräsentieren dabei komplementäre und sich immer wieder gegenseitig in Schach haltende Erzählambitionen: Während Jean Paul den Romanschreiber dazu anspornt, die Totalität des Irdischen in seinen Text zu integrieren, steht Hölderlin für die Seelenreise durch den Himmel, für die Sehnsucht nach dem Absoluten, der sinnlichen wie übersinnlichen Ekstase.
=== Accelerated consumer adoption === The pandemic dramatically increased public awareness of diagnostic testing and normalized at-home health monitoring. Self-testing kits for COVID-19 familiarized millions of consumers with the concept of collecting samples at home, reducing barriers to adoption of other DTC testing services. The blood sample segment dominated the self-testing market with approximately 35.19% revenue share in 2024.
Schröder (1993, 2002) reviewed the issue of CPA dosage and recommended a dosage of 200 to 300 mg/day for CPA as a monotherapy and a dosage of 100 to 200 mg/day for CPA in combined androgen blockade (that is, CPA in combination with surgical or medical castration). However, the combination of CPA with castration for prostate cancer has been found to significantly decrease overall survival compared to castration alone. Hence, the use of CPA as the antiandrogen component in combined androgen blockade would appear not to be advisable. When used by intramuscular injection to treat prostate cancer, CPA is used at a dosage of 300 mg once a week. The combination of CPA with an estrogen such as ethinylestradiol sulfonate or low-dose diethylstilbestrol has been used as a form of combined androgen blockade and as an alternative to the combination of CPA with surgical or medical castration.
Finally, rapG and rapH have been identified to code for enzymes that have a positive regulatory role in the preparation of rapamycin through the control of rapamycin PKS gene expression. Biosynthesis of this 31-membered macrocycle begins as the loading domain is primed with the starter unit, 4,5-dihydroxocyclohex-1-ene-carboxylic acid, which is derived from the shikimate pathway. Note that the cyclohexane ring of the starting unit is reduced during the transfer to module 1. The starting unit is then modified by a series of Claisen condensations with malonyl or methylmalonyl substrates, which are attached to an acyl carrier protein (ACP) and extend the polyketide by two carbons each. After each successive condensation, the growing polyketide is further modified according to enzymatic domains that are present to reduce and dehydrate it, thereby introducing the diversity of functionalities observed in rapamycin (figure 1). Once the linear polyketide is complete, L-pipecolic acid, which is synthesized by a lysine cycloamidase from an L-lysine, is added to the terminal end of the polyketide by an NRPS. Then, the NSPS cyclizes the polyketide, giving prerapamycin, the first enzyme-free product. The macrocyclic core is then customized by a series of post-PKS enzymes through methylations by MTases and oxidations by P-450s to yield rapamycin.
This process uses sun exposure as its thermal source, combined with natural airflow. It is also a traditional drying method to reduce the moisture of fruits by spreading them under the sun. Warmer temperatures evaporate the moisture, and lower humidity allows moisture to move quickly from the fruit to the air. However, there are many disadvantages associated with it, such as the longer time required to dry, the hot climate and daylight, and risk of invasion by animals and unwanted microorganisms.
Sources: en.wikipedia.org
=== Pollution control and bioremediation === Sewage can be treated with algae, reducing the use of large amounts of toxic chemicals that would otherwise be needed. Algae can be used to capture fertilizers in runoff from farms. When subsequently harvested, the enriched algae can be used as fertilizer. Aquaria and ponds can be filtered using algae, which absorb nutrients from the water in a device called an algae scrubber, also known as an algae turf scrubber. Agricultural Research Service scientists found that 60–90% of nitrogen runoff and 70–100% of phosphorus runoff can be captured from manure effluents using a horizontal algae scrubber, also called an algal turf scrubber (ATS). Scientists developed the ATS, which consists of shallow, 30-metre (100 ft) raceways of nylon netting where algae colonies can form, and studied its efficacy for three years. They found that algae can readily be used to reduce the nutrient runoff from agricultural fields and increase the quality of water flowing into rivers, streams, and oceans. Researchers collected and dried the nutrient-rich algae from the ATS and studied its potential as an organic fertilizer. They found that cucumber and corn seedlings grew just as well using ATS organic fertilizer as they did with commercial fertilizers. Algae scrubbers, using bubbling upflow or vertical waterfall versions, are now also being used to filter aquaria and ponds. The alga Stichococcus bacillaris has been seen to colonize silicone resins used at archaeological sites; biodegrading the synthetic substance.
=== Lipton Brisk === Brisk, formerly Lipton Brisk, is a ready to drink iced tea brand made and distributed primarily in North America by the joint venture between Unilever and PepsiCo. It differs from other iced tea brands in that phosphoric acid is added to the blend as a preservative, giving the beverage a distinctive sharp flavour.
In November 2025, United States President Donald Trump announced a deal with Novo to lower the costs of Ozempic, including monthly prices of about $245 for injectables and $149 for some oral versions for people on Medicare and Medicaid and for those who use his TrumpRx platform. In 2026, new obesity GLP-1 pills were launched, with patients getting their hands on them from Danish drugmaker Novo. Novo filed a federal lawsuit against Eli Lilly and Company in July 2026 in the District of New Jersey, alleging that Eli Lilly engaged in false advertising regarding its weight-loss and diabetes medications. The complaint accuses Lilly of misrepresenting comparative clinical data and omitting key information to gain an unfair advantage in the U.S. anti-obesity medication market.
== Function and Terminology == The “pre-” prefix of preproglucagon indicates that it is composed of proglucagon together with a signal peptide. The signal peptide is a 20 amino acid fragment that signals that the protein needs to be secreted out of the cell. Proglucagon has the “pro-“ prefix because it is a prohormone, which means it is an inactivate precursor that needs to be further modified in order to produce active hormone(s). In particular, proglucagon is cleaved (cut) into different active hormones depending on the organ. Omitting various inactive fragments, preproglucagon is cleaved into the following:
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.